Abstract
The levels of immunoreactive prostatic inhibin-like peptide (PIP), having follicle-stimulating hormone suppressing properties, were estimated in the sera and urine samples of patients with benign prostatic hyperplasia (BPH) and prostatic carcinoma (PC) as compared to age-matched controls. Significantly elevated serum PIP levels in BPH (107.8 ± 19 ng/ml) and PC (88.7 ± 9 ng/ml) patients were observed as compared to those in control men (10.2 ± 1 ng/ml). Unlike serum, in urine high levels of PIP in BPH (294 ± 49 μg/24 h) and extremely low levels in PC (23.6 ± 5 μg/24 h) patients were seen as compared to control values (137.6 ± 10 μg/24 h). Further-more, striking differences were observed between the urinary PIP levels of BPH and PC patients. The results of the present investigation thus indicate the possible use of urinary PIP as a biological marker for prostate cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
